Latest Regulatory Milestones News

Invex Therapeutics reports a net loss of $715,582 for H1 2026 while advancing its Exenatide program targeting neurological diseases, alongside notable board reshuffles.

Patrys Limited has appointed Dr Samantha South as its new CEO, aiming to leverage her biotech expertise to fast-track clinical development and commercialisation of its therapeutic antibody pipeline.

Tartana Minerals has made significant strides in expanding its silver exploration footprint with uncontested progress on EPM 27220, covering historic high-grade silver mines. The company also restates a robust Nightflower Exploration Target and plans extensive drilling in 2026.

Boab Metals has obtained the last major environmental approval needed to kickstart construction at its Sorby Hills Silver-Lead-Zinc Project in Western Australia, setting the stage for production in 2027.

Memphasys Limited has secured Therapeutic Goods Administration approval for its Felix™ System two months ahead of schedule, enabling immediate commercial sales and clinical use in Australia.

Altamin Limited has obtained a retrospective Environmental Impact Assessment approval for its Gorno Project in Italy, strengthening its regulatory footing and supporting strategic options for development.

Apiam Animal Health has secured court approval for its corporate scheme, paving the way for a fully franked special dividend payment next month.

Klevo Rewards Limited’s subsidiary Fly Wallet has secured key Mastercard compliance and earned over AUD 550,000 in incentives, marking a significant step in its payments platform evolution.

Island Pharmaceuticals secures FDA confirmation on Galidesivir’s development under the Animal Rule, unlocking a streamlined two-stage approval process and significant commercial incentives.

Terrain Minerals has initiated diamond drilling at its Smokebush Gold & Silver Project, advancing toward a maiden JORC Mineral Resource estimate targeted for mid-2026. The company’s exploration momentum continues with ongoing RC drilling at Lightning and upcoming programs at Wildflower.

Imricor Medical Systems has welcomed Oklahoma Heart Institute as the fourth U.S. site in its pivotal VISABL-AFL clinical trial, accelerating patient recruitment and the FDA approval pathway for its MRI-guided cardiac ablation technology.

Memphasys has lodged regulatory submissions for its Felix™ System in Australia and India, following CE Mark approval, while progressing UK market entry under the CE Mark transition framework.